Mealey's Antitrust/Unfair Competition - Ranbaxy, Teva Pay $300,000, End Pact Not To Challenge Generic Drug Applications

Mealey's Antitrust/Unfair Competition - Ranbaxy, Teva Pay $300,000, End Pact Not To Challenge Generic Drug Applications

NEW YORK - Generic drug manufacturers Ranbaxy Pharmaceuticals Inc. and Teva Pharmaceuticals USA Inc. have agreed to pay the State of New York $150,000 each and to end their "pay-to-delay" agreement relating to generic versions drugs, the New York Attorney General's Office announced Feb. 19 (In the Matter of the Investigation by Eric T. Schneiderman, et al., Assurance No. 14-034, N.Y., Atty. Gen.).

Find full version on lexis Advance®
Access this news story on lexis.com®